Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05996003 · ClinicalTrials.gov registry record · Phase 2

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase 2 study of Duchenne Muscular Dystrophy and DMD, sponsored by NS Pharma.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
20
Study locations

NCT05996003: Recruiting Phase 2 study of Duchenne Muscular Dystrophy and DMD, sponsored by NS Pharma.

NCT05996003 is a Phase 2 study of Duchenne Muscular Dystrophy and DMD that is actively recruiting participants, run by NS Pharma. The registered enrollment target is 20 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 19 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05996003, a Phase 2 study of Duchenne Muscular Dystrophy and DMD, is actively recruiting participants, sponsored by NS Pharma.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.

Conditions Studied

Duchenne Muscular Dystrophy DMD Exon 44

Interventions

  • DRUG NS-089/NCNP-02

Study Locations (20)

Pennsylvania

  • The Children's Hospital of Philadelphia (CHOP) - Philadelphia
  • University of Pittsburgh School of Medicine - Pittsburgh

Colorado

  • Children's Hospital Colorado - Aurora

Florida

  • Rare Disease Research, LLC - FL - Kissimmee

Georgia

  • Rare Disease Research - Atlanta

Illinois

  • Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago

Kansas

  • University of Kansas Medical Center (KUMC) - Kansas City

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Texas

  • UT Southwestern/Children's Health - Dallas

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-02-22
Est. Completion 2026-09-11
Phase Phase 2
NS Pharma

11 total trials

What NCT05996003 shows while recruiting

NCT05996003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which NS-089/NCNP-02 is the first listed.

NCT05996003 names 20 study sites across 19 states, led by Pennsylvania, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT05996003 about?

NCT05996003 is a clinical study titled "NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)". This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The stu...

What is the current status of trial NCT05996003?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-02-22. Estimated completion is 2026-09-11.

What conditions does trial NCT05996003 study?

This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, DMD, Exon 44.

What interventions are being tested in trial NCT05996003?

The interventions under investigation include: NS-089/NCNP-02 (DRUG).

Who is sponsoring clinical trial NCT05996003?

This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05996003 being conducted?

This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Duchenne Muscular Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05996003's enrollment target sits among peer trials

20 36th of 48 higher than 12 of 48 other Duchenne Muscular Dystrophy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05996003

Source: ClinicalTrials.gov NCT05996003, the US trial registry maintained by the National Library of Medicine. NCT05996003 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.